He called UnitedHealth “unbelievable at capital deployment,” adding that the company has “created a tremendous amount of value by continuing to buy physicians’ practices and ambulatory-service centers.” He also pointed to the vast improvement in efficiency as more procedures are performed outside of hospitals.The first is a new gene therapy for people suffering from hemophilia A, consisting of an intravenous “engineered virus” designed to cause the liver to produce Factor 8, a protein that helps blood to clot.